comparemela.com

Latest Breaking News On - Tsx venture exchange nrx - Page 1 : comparemela.com

NurExone Launches Licensing Efforts for ExoTherapy

NurExone Biologic launches licensing efforts for its ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes. .

Lior shaltielEva reuterVenture exchangeRegulation services providerNurexone biologic incThesis capital incCompany exotherapyCompany or nurexoneExone biologicLoading extracellularBat ami gotlivCentral nervous systemOrphan drug designationExecutive officerTsx venture exchange nrxNurexone biologic inc

NurExone and Inteligex Kick Off Chronic Spinal Cord Injury

NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market.

Medien gmbh bullvestorLior shaltielEva reuterPaul bradshawTel aviv universityCompany or nurexoneInteligex incNurexone biologic incIsrael institute of technologyThesis capital incVenture exchangeExone biologicSpinal cord injuryExone announces engagement agreementVestor medien gmbhIsrael institute

NurExone Biologic Extends Spinal Cord Injury Therapy

NurExone Biologic expands its portfolio of products to address spinal cord injuries & neuron regeneration in CNS indications.

Eva reuterNisim peretsLior shaltielCompany exotherapyCompany or nurexoneCompany annual information formTel aviv universityThesis capital incIsrael institute of technologyNeural networkNurexone biologic incExone biologicPeri neural networkIsrael instituteExecutive officerAnnual information form

NurExone Biologic Receives FDA Orphan-Drug Designation,

NurExone Biologic Receive FDA Orphan-Drug Designation to its ExoPTEN Therapy for Acute Spinal Cord Injury Treatment .

United statesEva reuterLior shaltielDrug administrationThesis capital incNurexone biologic ltdTel aviv universityIsrael institute of technologyCompany exoCompany exotherapyNurexone biologic incCompany or nurexoneExone biologicOrphan drug designationNurexone biologicIsrael institute

NurExone Moves Forward Towards Human Clinical Trials,

The FDA’s response indicated that the planned toxicity study strategy is acceptable under FDA guidelines and large-scale animal studies will not be.

Lior shaltielCompany exoDrug administrationCompany or nurexoneIsrael institute of technologyCompany exotherapyTel aviv universityNurexone biologic incExone biologicPre investigational new drugIsrael instituteExecutive officerTsx venture exchange nrxNurexone biologic incReind meetingClinical trials

vimarsana © 2020. All Rights Reserved.